Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis Teva Pharmaceutical Industries Ltd. and Active Biotech announced today the results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus that can lead to chronic kidney failure1.
June 12, 2013 - Business Wire via Yahoo! Finance